Presidential Proclamation: National Diabetes Month 2024
October 31, 2024
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
The Frame
This proclamation highlights federal policy changes regarding insulin pricing and diabetes research funding that directly impact the out-of-pocket medical expenses for millions of Americans.
Potentially affected actors named in the source documents. Mention is not a position.
Medicare beneficiaries
This group is subject to new caps on insulin costs and annual out-of-pocket drug spending.
Drug manufacturers
These companies are subject to new Medicare drug price negotiations and requirements to pay rebates if price increases exceed inflation.
School systems
Schools are provided with new standards and options regarding the nutritional value and sourcing of ingredients for school meals.
Last recorded activity October 31, 2024.
Next step not available in the current record.
Summary
Key Facts
- Over 38 million Americans, or 1 in 10 people, have diabetes.
- The Inflation Reduction Act caps insulin costs at $35 per month for Medicare beneficiaries.
- Starting in 2025, out-of-pocket drug costs for Medicare recipients will be capped at $2,000 per year.
- The administration secured $4 billion for the Advanced Research Projects Agency for Health to research diabetes and other diseases.
- The White House Challenge to End Hunger and Build Healthy Communities has secured over $10 billion in public and private commitments.
Frequently Asked Questions
How much does insulin cost for Medicare patients under current law?
What is the annual out-of-pocket limit for drugs for Medicare patients starting in 2025?
Why It Matters
This proclamation highlights federal policy changes regarding insulin pricing and diabetes research funding that directly impact the out-of-pocket medical expenses for millions of Americans.
News Coverage
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Medicare Drug Cost Caps
The document highlights a transition toward federal price negotiation and out-of-pocket spending caps for Medicare, marking a shift in federal pharmaceutical policy.
Connected Entities
Sources
www.federalregister.gov
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy40Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz25Current news / social attention level
Publisher tools